The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 613-621

  Hamilton, Marta ^a   Wolf, Julie L ^b   Drolet, Daniel W ^c   Fettner, Scott H ^d   Rakhit, Ashok K ^e   Witt, Karsten ^f   Lum, Bert L ^g  

^a Hamilton Consulting Group LLC   (United States)

^b Novella Clinical   (United States)

^c SomaLogic Inc   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

^f KW Biotech Consulting   (United States)

^g GENENTECH INC   (United States)

Author keywords

CYP3A4; Dose adjustment; Erlotinib; Pharmacokinetics; Rifampicin

Indexed keywords

CYTOCHROME P450 3A4; ERLOTINIB; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; DISORIENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INDUCTION; FACE ERYTHEMA; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE URINE LEVEL; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SMOKING; YOUNG ADULT;

ADULT; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RIFAMPIN; YOUNG ADULT;

EID: 84896048044     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2390-3     Document Type: Article

References (28)

1. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132 (Pubitemid 41058344)
2. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960-1966 (Pubitemid 46972777)
3. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo controlled phase 3 study. Lancet Oncol 11(6):521-529
4. Tarceva® Full Prescribing Information, Astellas Pharma US, Inc., and Genentech, Inc, May 2013
5. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239-246
6. National Comprehensive Cancer Network (2013) NCCN Clinical practice Guidelines in Oncology; Non-Small-Cell Lung Cancer Version 2.2013. http://www.nccn.com
7. Hamilton M, Wolf JL, Rusk J et al (2006) Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12(7 Pt 1):2166-2171
8. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Reik M et al (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer based simulation (SimCYP™) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31-41
9. Calvert H, Twelves C, Ranson M, Anthoney A, Plummer R, Fettner S et al. (2005) The effect of erlotinib (Tarceva™) on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients - preliminary results. J Clin Oncol ASCO Ann Mtg Proceed 23(16s, Part I of II): 3076
10. Ohnhaus E, Breckenridge AM, Park BK (1989) Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36:39-46 (Pubitemid 19052008)
11. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M et al (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34(3):420-426 (Pubitemid 43290900)
12. Tanaka C, Yin OQ, Smith T et al (2011) Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 51(1):75-83
13. Yeo KP, Lowe SL, Lim MT et al (2005) Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. Br J Clin Pharmacol 61(2):200-210 (Pubitemid 43382613)
14. Saima S, Furuie K, Yoshimoto H et al (2002) The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. Br J Clin Pharmacol 53(2):203-206 (Pubitemid 34264277)
15. Israili ZH, Rogers CM, El-Attar H (1987) Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol 27:78-83 (Pubitemid 18049894)
16. Correia MA (2003) Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev 35(2 & 3):107-143 (Pubitemid 37048294)
17. Reitman ML, Chu X, Cai X et al (2011) Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234-242
18. O'Reilly RA (1975) Interaction of chronic daily warfarin therapy and rifampicin. Ann Intern Med 83:506-508
19. Lam JL, Shugarts SB, Okochi H, Benet LZ (2006) Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319(2):864-870
20. Kirby BJ, Collier AC, Kharasch ED et al (2012) Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 40:610-616
21. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations Draft Guidance February 2012. Accessed 9 Apr 2013 http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm
22. Elmeliegy MA, Carcaboso AM, Tagen M et al (2011) Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17(1):89-99
23. Li Y, Xu J, Lai G et al (2012) Metabolic switching of BILR 355 in the presence of ritonavir. Drug Metab Dispos 40(6):1130-1137
24. Shi Z, Peng XX, Kim IW et al (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67(22):11012-11020 (Pubitemid 350145931)
25. Li J, Cusatis G, Brahmer J (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6(3):432-438 (Pubitemid 47328313)
26. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19(13):3267-3279 (Pubitemid 32591445)
27. Prados MD, Lamborn KR, Chang S et al (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8(1):67-78 (Pubitemid 43154453)
28. Abbas R, Fettner S, Riek M, Bulsara S, Pantze M, Hamilton M, Frohna P, Rakhit A (2003) A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc Am Soc Clin Oncol 22:137 (abstr 548)